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A 
fundamental problem in the 
treatment of tuberculosis (TB) 
is the long duration of therapy 
required for cure. The recalcitrance 
of Mycobacterium tuberculosis (MTB) 
to eradication is thought to result 
from its achieving a nonreplicating 
(dormant) state in the host. Because 
virtually all classes of antibiotics require 
bacterial replication for their action, 
the nonreplicating state is thought to 
render MTB phenotypically resistant to 
otherwise bactericidal antibiotics.
Tuberculosis drug discovery efforts 
have been guided by the belief that 
MTB achieves this nonreplicating state 
as the result of speciﬁ  c interactions 
with the host, particularly residence 
in certain types of tuberculous 
granulomas. This belief has placed 
the imperative on understanding and 
overcoming TB-speciﬁ  c mechanisms 
by which the nonreplicating state is 
achieved. Yet, it is also known that 
many other pathogenic bacteria 
display phenotypic drug resistance 
in vivo, accounting for the need for 
longer durations of antibiotic therapy 
than would be predicted from the time 
required for in vitro bacterial killing. 
Only recently has attention been 
given to these general mechanisms to 
explain the need for prolonged TB 
therapy.
In this article, we consider general 
versus MTB-speciﬁ  c models of 
phenotypic antibiotic resistance (see 
Glossary) in light of our review of 
human TB treatment data. These 
data suggest that the duration of 
therapy required for cure correlates 
with overall bacterial burden. This 
correlation between bacterial burden 
and time to cure is not unique to TB, 
as it has been found in other bacterial 
infections, both acute and chronic. 
High bacterial burden infections, in 
turn, are associated with an increased 
frequency of phenotypically drug-
resistant bacteria. We argue that 
understanding and countering general 
bacterial mechanisms of phenotypic 
antibiotic resistance may hold the key 
to reducing the duration of treatment 
of all recalcitrant bacterial infections, 
including TB.
Types and Consequences of MTB 
Drug Resistance
Soon after the discovery of streptomycin 
it became clear that while many 
patients with TB treated with this drug 
initially improved dramatically, most 
developed streptomycin-resistant strains 
so that there was little improvement in 
mortality over untreated patients [1]. 
The development of new antibiotics 
led to the realization that there were 
two requisites for effective cure: 
treatment with multiple antibiotics 
and long therapy [2]. Indeed, the 
minimum length of treatment and 
number of drugs required for cure has 
been more carefully tested for TB than 
for most infectious diseases (see [3] 
and Table S1).
The need for multidrug and long-
term therapy stems from two different 
drug resistance mechanisms. MTB 
can exhibit genetic resistance that 
is heritable and ﬁ  xed, as well as 
phenotypic, reversible resistance to 
administered antibiotics. The presence 
of genetic drug resistance in some or 
all of the infecting bacteria dictates 
the need for multidrug therapy [2,4]. 
The greater the bacterial burden, the 
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Glossary
Antibiotic indifference: A subtype of 
phenotypic resistance to antibiotics 
due to decreased or absent bacterial 
growth of the entire bacterial population, 
generally in response to adverse 
environmental conditions, such as host 
defense reactions.
Bioﬁ  lms: Multicellular bacterial 
communities encased in a matrix which 
demonstrate resistance to antibiotic 
killing in the absence of genetic 
resistance mechanisms. 
Dormancy: A nonreplicating state, 
thought to be achieved by M. tuberculosis 
in the host, that renders the bacteria 
phenotypically resistant to killing by 
both host immune mechanisms and 
antibiotics.
Latency: Clinically asymptomatic 
infection with M. tuberculosis.
Persisters: A stochastically determined 
subset of bacteria that arise in an 
otherwise growing population of bacteria 
and are in a state of slow or non-growth, 
rendering them resistant to antibiotics.
Phenotypic antibiotic resistance: 
A general term for the phenomenon 
by which genetically homogeneous, 
antibiotic-susceptible bacterial 
populations (or subpopulations) become 
transiently insensitive to antibiotic killing.PLoS Medicine  |  www.plosmedicine.org 0436
more likely that it contains genetically 
resistant mutants [5]. Therapy failure 
due to genetic resistance is related to 
the frequency of preexisting resistant 
mutants and their enrichment 
by selective pressures imposed by 
inadequate therapy [4]. Simultaneous 
use of multiple anti-TB drugs makes it 
less likely that a mutant resistant to a 
single agent will survive.
MTB also exhibits phenotypic drug 
resistance. In patients who relapse 
early after appropriate multidrug 
therapy, the bacteria remain 
genetically susceptible to the initial 
antibiotics and cure is achieved by 
additional treatment with the same 
regimen [6,7]. This phenomenon 
may be due to a subpopulation of 
nonreplicating bacteria that survives 
until anti-tuberculous therapy is 
stopped and causes relapse as it 
resumes growth in the absence of 
antibiotics. Long-term antibiotic 
treatment may cure the infection 
by eradicating these bacterial 
populations as they periodically leave 
the nonreplicating state. Further 
supporting this theory of MTB’s 
development of a nonreplicating and 
therefore phenotypically resistant state 
in vivo is the observed discrepancy 
between in vitro and in vivo antibiotic 
killing [8].
Treatment of MTB with isoniazid 
(INH), a drug that targets cell wall 
synthesis, causes a 3-log reduction 
in broth culture in two hours [9,10], 
whereas more than 14 days of therapy 
are required to achieve a 3-log 
reduction in viable bacterial counts in 
the sputum during active TB [11,12] 
and several months of treatment 
are required to eradicate latent TB 
(Table 1). The role of pyrazinamide 
in shortening TB therapy to six 
months may also suggest the existence 
of a nonreplicating population in 
vivo, as, unlike other anti-TB drugs, 
pyrazinamide is more active against 
nonreplicating than actively replicating 
MTB in vitro [13,14]. Phenotypic 
antibiotic resistance likely accounts 
for the need for longer antibiotic 
therapy in many bacterial infections, 
presenting a universal obstacle to the 
treatment of infectious diseases ([15–
17] and Table 1).
The impact of phenotypic drug 
resistance on TB treatment outcomes 
is particularly dire. In the absence of 
an effective vaccine, TB eradication 
is dependent on curing infected 
individuals who are either contagious 
or may become contagious after 
reactivation of latent infection. The 
relative lack of protective immunity 
provided by natural infection makes 
control all the more dependent on 
complete bacterial eradication from 
the population, since individuals who 
are cured of TB remain vulnerable to 
reinfection [18,19]. Drug resistance, 
and the consequent need for long-
term multidrug therapy have stymied 
TB eradication efforts particularly in 
poor countries with the highest disease 
burden. Poor adherence to therapy 
also has led to an alarming increase 
in multidrug-resistant (MDR) and 
extensively drug-resistant (XDR) strains 
[20], which are associated with high 
morbidity and mortality [21,22]. Hence 
the critical need for new drugs to 
shorten treatment of drug-sensitive TB, 
and to treat MDR- and XDR-TB.
Overview of TB Pathogenesis 
and Pathology
A review of TB pathogenesis and 
pathology will facilitate the assessment 
of the models proposed for the 
mechanisms of phenotypic antibiotic 
resistance of MTB. MTB reaches the 
alveoli in small, aerosolized particles 
and is transported into tissues within 
host macrophages, which aggregate 
with other immune cells to form 
granulomas, the hallmark lesion of 
TB. In immunocompetent individuals, 
there are two main outcomes of initial 
infection: the development of active 
TB or the establishment of a clinically 
asymptomatic (latent) infection. Active 
disease is associated with a wide range 
of granuloma structures [23–25], 
including bacteria-laden, necrotic 
(caseating) lesions undergoing central 
liquefaction and large open cavities. 
Patients with active disease also harbor 
lesions in various stages of healing, 
including closed granulomas with 
hard, central caseum, and ﬁ  brotic 
and calciﬁ  ed lesions. These latter 
types of lesions with lower bacterial 
burdens [23,26] are the only lesion 
types detected in latent TB [23]. 
However, the actual physical location of 
viable bacteria during latent infection 
remains a topic of considerable debate. 
In latently infected individuals, viable 
bacteria or bacterial DNA have been 
detected outside of granulomas in 
apparently normal tissue [26,27]. In 
contrast, immunocompromised (e.g., 
HIV-infected) individuals tend to 
develop disease with poorly organized, 
noncaseating lesions that contain 
numerous bacteria [28].
Table 1. Phenotypic Antibiotic Resistance In Vivo Is Common to Many Bacterial Pathogens
Organism Antibiotic 3 Log Reduction 
In Vitroa
Disease State Duration 
of Therapy
“Cure Rate”
In Vivob
References
MTB INH 2 hours Latent TB 3 months 31% [9,10,81]
6 months 69%
12 months 93%
E. coli β-lactam 30 minutes Cystitis 1 dose 66% [82,83]
3 days 82%
8 days 88%
Staphylococcus aureus β -lactam +/- amino-
glycoside
24 hours Bacteremia or R-sided 
endocarditis
2 weeks 92%–100% [84–88]
L-sided endocarditis 4–6 weeks 50%–82% [89,90]
aExponential phase cultures.
bCure rate for latent TB is deﬁ  ned as the percent reduction in cases of active TB in individuals treated with INH versus individuals treated with placebo. Cure rate for E. coli cystitis and 
S. aureus bacteremia or endocarditis is deﬁ  ned as resolution of clinical symptoms and/or bacteriologic proof of cure.
doi:10.1371/journal.pmed.0040120.t001
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In summary, during active disease, 
numerous bacteria are found in 
highly organized, caseating, and 
cavitary lesions of immunocompetent 
individuals or in poorly organized, 
noncaseating granulomas of severely 
immunocompromised individuals, 
whereas the lesions present in latent 
TB contain few bacteria and viable 
bacteria may be present outside of 
discernible granulomas. The lesions 
characteristic of latency are also found 
in immunocompetent individuals with 
active disease.
TB-Speciﬁ  c Model of In 
Vivo–Induced Phenotypic 
Antibiotic Resistance
The ﬁ  rst step in understanding MTB 
phenotypic drug resistance is to 
address whether it is mediated by TB-
speciﬁ  c mechanisms as has been widely 
postulated, or by mechanisms common 
to all bacteria. TB-speciﬁ  c models 
suggest that environmental conditions 
in speciﬁ  c granuloma types, in 
particular those associated with latent 
disease, induce nonreplicating bacterial 
populations and thereby antimicrobial 
resistance [29–33]. This nonreplicating 
state is thought to be an MTB-speciﬁ  c 
response to conditions found within 
closed granulomas such as hypoxia 
and/or nitric oxide production. 
According to this model, exposure to 
these conditions leads to the expression 
of a discrete set of genes known as 
the dormancy regulon that are in 
turn responsible for maintaining the 
bacilli in the nonreplicating and hence 
resistant state [29,34–36]. The theory 
that TB-speciﬁ  c, environmentally 
induced mechanisms lead to sustained 
phenotypically drug-resistant bacterial 
populations has led to an emphasis 
on understanding speciﬁ  c host 
environments such as hypoxia and 
the speciﬁ  c bacterial gene expression 
programs they induce as a basis for 
developing drugs that intercept this 
host–bacterial interface [29–33,35–37].
The main argument favoring the 
environmentally induced in vivo 
dormancy program speciﬁ  c to MTB 
is based on observed differences in 
bacterial growth in vitro depending 
on the type of human lesion from 
which the bacteria were isolated 
[24,25]. Cavitary lesions resected 
from treated patients contained drug-
resistant MTB that grew in a normal 
time frame (eight weeks), whereas 
“latent”-appearing (closed caseous) 
lesions from these same patients often 
contained drug-sensitive bacteria that 
grew only after three to ten months of 
incubation. These observations were 
interpreted to mean that the bacteria 
from the cavitary lesions were actively 
replicating and thus susceptible to the 
administered antibiotics. Therefore, 
following antibiotic therapy, this niche 
became populated by the growth of 
the drug-resistant mutants that were 
selected for during drug treatment.
In contrast, the bacteria in the closed 
lesions were thought to have been 
driven into a nonreplicating state by 
adverse conditions present within the 
lesion prior to antibiotic therapy. The 
nonreplicating state of the bacteria in 
these lesions was felt to account for 
both characteristics observed in vitro: 
the slower growth due to the need 
to overcome this dormant state as 
well as drug sensitivity owing to their 
never having been acted upon by the 
antibiotic in vivo. These differences 
were felt to be unlikely to be due to 
a lack of drug exposure in the closed 
lesions, because several of the agents 
used have been shown to penetrate 
both types of lesions [23,38]. However, 
these ﬁ  ndings could have had an 
alternate explanation, which was not 
considered. The slower growing, drug-
sensitive bacteria could have been 
present in the open lesions but their 
in vitro detection masked by the more 
rapidly growing, drug-resistant bacteria. 
If true, this would mean that the 
nonreplicating state is not speciﬁ  cally 
induced by the environment present in 
the closed lesions but is present in all 
bacterial populations and lesion types 
in vivo.
Do Human Pulmonary TB 
Treatment Trials Inform Us 
about Mechanisms of Phenotypic 
Antibiotic Resistance?
Another problem with the TB-speciﬁ  c 
model is that it implicates the lesions 
that are associated with few bacteria in 
inducing bacterial phenotypic antibiotic 
resistance. However, short-course 
treatment trials for pulmonary TB 
suggest that the duration of treatment 
required to prevent relapse of active 
disease is directly proportional to 
doi:10.1371/journal.pmed.0040120.g001 
Figure 1. Duration of Curative Therapy for Pulmonary Tuberculosis Correlates Directly with 
Organism Burden
Pulmonary TB with a low bacterial burden (smear negative, culture negative [Cx-]; white bars) 
requires the shortest duration of four-drug therapy to achieve relapse rates <10%. Moderate 
burden (smear negative, culture positive [Cx+]; grey bars) patients require intermediate treatment 
courses, while high burden (smear positive, Cx+; black bars) cases require the longest duration of 
therapy. All patients were HIV negative and were treated with six months of therapy consisting 
of streptomycin (S), isoniazid (H), rifampin (R), and pyrazinamide (Z) during the intensive phase, 
followed by SHRZ or HR combinations in the continuation phase. Data for the ﬁ  gure were obtained 
from references [78–80,91–95].
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the organism burden, rather than 
the predominant type of granuloma 
microenvironment present (Figures 1 
and 2, Table S1). Smear-positive and 
cavitary disease states are associated with 
the highest organism burden [12,39] 
and require the longest duration of 
therapy to effect cure (Figures 1 and 
2). In contrast, both HIV-positive and 
HIV-negative individuals with latent TB, 
which is characterized by low bacterial 
burden, are readily “cured” with single-
drug therapy (Table S1). Twelve months 
of INH therapy in adherent populations 
with a low risk of reinfection leads to a 
92%–93% reduction in the rate of active 
disease [40,41]. This reduction, using a 
single drug, is comparable to that seen 
in treating high-burden, active disease 
with multidrug therapy, underscoring 
the importance of bacterial burden 
as one of the main determinants of 
successful treatment. The high relapse 
rate of cavitary disease may also be 
related to poor penetration of the cavity 
by antibiotics, due to the dense, ﬁ  brous 
capsule surrounding these lesions [23]. 
However, some studies have shown that 
antibiotics do penetrate such lesions 
[23,38]. This point is underscored by 
the growth of resistant bacteria from 
these lesions in the studies described in 
the previous section [24,25].
An alternative explanation for the 
long duration of therapy required to 
treat active disease states associated 
with the highest bacterial burden 
(e.g., smear positive and cavitary 
disease) is that those individuals with 
active disease have a greater burden 
of bacteria present in “latent-type” 
lesions than do those with low burden 
or latent disease. According to this 
interpretation, it is the total burden of 
bacteria present within these “latent” 
lesions that dictates the duration of 
therapy rather than the overall burden. 
However, this interpretation fails to 
explain the ﬁ  nding that HIV-infected 
individuals who tend to have poorly 
formed, noncaseating granulomas 
with high bacillary burdens [28] also 
require long durations of therapy 
(Figure 2 and Table S1) [28]. Further, 
the lesion-speciﬁ  c model does not 
account for the ﬁ  ndings that MTB 
exhibits nonreplicating states [42,43] 
and phenotypic drug resistance [44] 
during experimental infection of the 
mouse, an animal that forms poorly 
organized macrophage and lymphocyte 
aggregates that do not resemble 
human, caseating lesions. Together, 
these observations are most consistent 
with the conclusion that phenotypically 
drug-resistant MTB is present in all 
lesions rather than being restricted to 
“latent” granuloma environments.
Non-TB Speciﬁ  c Models 
to Explain the Problem of 
Phenotypic Drug Resistance
The human treatment trial data are 
most readily explained by a model 
in which infections characterized by 
the highest organism burden (be it 
in cavitary lesions, caseating lesions 
undergoing liquefaction, or poorly 
formed noncaseating granulomas 
typical of advanced HIV coinfection) 
also have the highest number of 
phenotypically drug-resistant bacteria. 
Because high organism burden is 
associated with phenotypic resistance 
in other infectious diseases, we 
propose that the mechanisms are 
similar in MTB and other pathogenic 
bacteria. We will describe the possible 
mechanisms brieﬂ  y here; for more 
detailed reviews of speciﬁ  c mechanisms 
see references [15–17,45,46].
Killing rates of actively growing MTB 
cultures are dramatically greater than 
killing rates of stationary-phase MTB 
cultures, in which the bacteria are 
resistant to killing in the absence of 
genetic resistance mechanisms [9,10]. 
This phenomenon had previously 
been described in other bacterial 
systems and the term antibiotic 
indifference was coined to describe 
the ﬁ  nding that bacteria that are 
not dividing, due to some inhibitory 
environmental condition, are resistant 
to killing by most antibiotics [47]. 
This phenomenon is not limited to 
in vitro culture systems. For example, 
the dose of penicillin required to 
cure experimental infections in 
animals is proportional to the total 
bacterial burden (both inoculum 
size and duration of infection). As 
doi:10.1371/journal.pmed.0040120.g002
Figure 2. Duration of Curative Therapy Is Longest for Disease States Associated with High-
Organism Burden Lesions
(A) Active TB associated with cavitary lesions requires longest duration of therapy to cure. Treated 
pulmonary TB with open lesions and the highest bacterial burden (cavitary lesions with positive 
sputum cultures [Cx+] after two months of therapy; black bars) is associated with higher rates of 
relapse than are disease states associated with closed lesions (noncavitary, culture negative [Cx-] 
at two months; white bars, and noncavitary, Cx+ at two months; dark gray bars) or with lower 
bacterial burdens (noncavitary, Cx- at two months; white bars, or cavitary, Cx- at two months; light 
gray bars). All patients were HIV negative and received isoniazid (H), rifampin (R), pyrazinamide 
(Z), and ethambutol (E) or streptomycin (S) during the intensive phase followed by HR or H plus 
rifapentine (P) in the continuation phase. 
(B) Active disease states characterized by well-organized (HIV-) or poorly organized (HIV+) lesions 
require the same duration of therapy for cure. The relapse rate for high-burden (smear-positive) 
disease states associated with well-organized, cavitary lesions (HIV-; black bars) or loosely 
organized, noncaseating lesions (HIV+; white bars) treated with standard therapy (EHRZ for two 
months followed by HR for four months) is the same. Data for HIV+ and HIV- individuals were 
obtained from references [96,97].
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the infection progresses, bacterial 
growth slows and eventually stops due 
to a variety of inhibitory conditions 
encountered in the host, rendering 
the residual population phenotypically 
antibiotic resistant [47–49]. One 
potential mechanism for MTB 
dormancy and phenotypic antibiotic 
tolerance in vivo is the development 
of antibiotic indifference in response 
to host defense mechanisms or 
nutrient deprivation. Although 
nutrient deprivation has long been 
proposed as one of the signals leading 
to mycobacterial dormancy, this 
mechanism need not be restricted to 
speciﬁ  c granuloma pathologies and is 
clearly not unique to MTB.
In addition to drug indifference, 
non-inherited drug resistance can 
also be explained by the observation 
that populations of actively growing 
bacteria contain a specialized, 
nonreplicating subpopulation known 
as persister cells [50]. Like drug-
indifferent bacteria, these persister 
cells remain genetically drug sensitive 
but are phenotypically drug resistant, 
and their number increases with total 
organism burden [51]. Although the 
initial establishment of the persister 
population is likely to be stochastic 
[52], the magnitude of this population 
may be further inﬂ  uenced by speciﬁ  c 
conditions operant in vivo such 
as growth in macrophages [53] or 
bioﬁ  lms [54]. For example, Legionella 
pneumophila grown in macrophages 
is more antibiotic resistant than 
broth-grown bacteria, suggesting that 
intramacrophage growth enriches 
phenotypically antibiotic-resistant 
populations [53]. This might occur 
because host-killing mechanisms 
may also target actively replicating 
bacteria [46]. Further, bacteria that 
have incurred DNA damage, perhaps 
as a result of host-killing mechanisms, 
undergo replication arrest to allow for 
DNA repair, rendering them transiently 
insensitive to antibiotic killing [55]. 
Some antibiotics actually induce DNA 
repair systems [56], halting bacterial 
division and theoretically rendering 
these bacteria even more resistant to 
therapy.
The molecular mechanisms of 
persister formation are beginning 
to be elucidated and include growth 
arrest secondary to the action of 
toxin–antitoxin modules [57,58]. The 
toxin portion of these modules acts 
to cleave mRNAs positioned in the 
ribosome, leading to translational and 
growth arrest [59]. Numerous putative 
toxin–antitoxin modules are found in 
the MTB genome [60,61] and some 
of these have been shown to cause 
translational arrest when expressed 
in Escherichia coli [62], but their 
role(s) in persister formation, in vivo 
survival, and/or drug indifference are 
unknown. relA, a gene involved in the 
bacterial response to starvation, 
has also been shown to play a role in 
some types of persister formation in 
E. coli [63]. Although a potential role 
for relA in mycobacterial phenotypic 
drug resistance has not been shown, 
relA is required for chronic infection 
in the mouse model of TB [64], 
suggesting a possible connection to 
mechanisms of resistance to both host- 
and antibiotic-mediated killing.
Studies of other chronic bacterial 
infections suggest that bioﬁ  lm 
formation is responsible for the 
relative in vivo resistance to antibiotic 
killing [65]. Bioﬁ  lms are multicellular 
bacterial communities encased in a 
matrix and bacteria within bioﬁ  lms are 
phenotypically resistant to antibiotic 
killing when compared to growing 
planktonic cells [66]. Examples 
of important bioﬁ  lm infections 
in humans include Pseudomonas 
aeruginosa lung infections in cystic 
ﬁ  brosis, endocarditis, and device-
related infections. Key aspects of MTB 
biology are reminiscent of bioﬁ  lm 
behavior. For example, MTB in liquid 
culture grows as large clumps of cells 
known as cords. The ability to cord 
in culture correlates with virulence 
[67–69], suggesting that the capacity 
to grow in a multicellular community 
is an important determinant of MTB 
survival in the host. MTB may also be 
found in a bioﬁ  lm-like state in vivo. 
For example, large clumps of bacteria 
reside in an acellular matrix in certain 
human lesions, such as caseating 
lesions undergoing liquefaction [23]. 
Bioﬁ  lms of other mycobacterial species 
have been shown to be phenotypically 
antibiotic resistant [70,71] and 
M. avium bioﬁ  lm-associated genes 
are required for mouse infection 
[72], further supporting the notion 
that bioﬁ  lms may play key roles in 
mycobacterial drug resistance and 
virulence.
The phenotypic resistance to 
antibiotics exhibited by bacteria 
within bioﬁ  lms is likely multifactorial. 
Proposed mechanisms of resistance 
include poor antibiotic penetration of 
the bioﬁ  lm, expression of bioﬁ  lm genes 
that confer resistance, and the presence 
of different microenvironments in the 
bioﬁ  lm that lead to different growth 
rates and thus differing antibiotic 
sensitivity [45,65]. One prominent 
school of thought is that the bioﬁ  lm 
environment may also enrich the 
formation of persister cells [54,73]
Summary and Proposed Areas 
of Research
New drugs that target nonreplicating 
bacteria are likely to revolutionize 
Five Key Papers in the Field
1. Canetti G, 1955 [23] A seminal text 
describing the pathology of human 
pulmonary tuberculosis with particular 
focus on the bacillary content of 
different types of lesions.
2. Vandiviere HM et al., 1956 [25] A 
detailed description of growth rates 
and antibiotic resistance patterns of 
M. tuberculosis isolated from different 
types of human tuberculous lesions, 
which has strongly inﬂ  uenced thinking 
in the ﬁ  eld regarding mechanisms 
of bacterial phenotypic antibiotic 
resistance in vivo.
3. Balaban NQ et al. , 2004 [52] Provides 
the ﬁ  rst direct evidence that persisters 
are a preexisting population of non-
dividing cells within a growing culture 
using ground-breaking techniques to 
study persisters at the single cell level.
4. Keren I et al., 2004 [57] First paper 
to describe global gene expression 
proﬁ  les in an isolated population 
of antibiotic-treated persister cells, 
supporting the role of toxin–antitoxin 
modules in persister biology. Later 
studies of naïve persisters have 
conﬁ  rmed these results.
5. Hong Kong Chest Service/
Tuberculosis Research Centre, 
Madras/British Medical Research 
Council, 1984, 1987, and 1989 
[78–80] A series of controlled trials 
of varying treatment durations for 
both smear-negative and -positive 
pulmonary tuberculosis that conﬁ  rm 
bacillary burden to be one of the main 
determinants of duration of therapy 
required for cure.
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TB therapy. Such agents have the 
potential not only to treat MDR and 
XDR strains but also to dramatically 
shorten the duration of curative 
therapy. Shorter treatment times will 
likely translate into higher patient 
adherence, reduced transmission, and 
decreased drug resistance, leading 
in turn to diminished mortality and 
substantial gains in tuberculosis control 
efforts. For example, mathematical 
models based on the current situation 
in Southeast Asia estimate that a two 
month regimen could prevent ~25% 
of deaths and ~20% of new cases over 
a 18-year period compared to current 
treatment regimens [74].
A major obstacle for such truly short-
course therapy is the development 
of phenotypic antibiotic resistance in 
vivo. This phenomenon is common 
to all bacteria and these resistant 
populations may be enriched under a 
variety of conditions that are operant 
in vivo, such as intracellular growth, 
DNA damage, exposure to other 
antimicrobials, and bioﬁ  lm formation. 
In addition to studying possible TB-
speciﬁ  c mechanisms of phenotypic drug 
resistance, we suggest that the study 
of mycobacterial persister formation 
and bioﬁ  lm-like growth states may 
lead to drug discovery. Additionally, a 
better understanding of mechanisms 
of phenotypic antibiotic resistance in 
other pathogenic bacteria will likely 
have implications for MTB therapy. 
Given our current understanding, the 
development of antibiotics that are 
effective against non-dividing bacteria 
is of potential great importance 
[75]. Promising candidates under 
investigation include the ATP synthase 
inhibitor R207910 [76]; however, 
MTB mutants resistant to this agent 
have been found even before clinical 
trials have been completed [77]. 
Development of additional drugs that 
target bacterial or host programs that 
induce phenotypic antibiotic resistance 
mechanisms will be aided by a better 
understanding of the physiology of this 
MTB population and the conditions 
that induce or enrich it.  
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